A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer
- PMID: 18089803
- DOI: 10.1158/0008-5472.CAN-07-2343
A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer
Abstract
By screening a tissue microarray of invasive breast tumors, we have shown that the receptor tyrosine kinase RET (REarranged during Transfection) and its coreceptor GFR alpha 1 (GDNF receptor family alpha-1) are overexpressed in a subset of estrogen receptor-positive tumors. Germ line-activating oncogenic mutations in RET allow this receptor to signal independently of GFR alpha 1 and its ligand glial cell-derived neurotrophic factor (GDNF) to promote a spectrum of endocrine neoplasias. However, it is not known whether tumor progression can also be driven by receptor overexpression and whether expression of GDNF, as has been suggested for other neurotrophic factors, is regulated in response to the inflammatory microenvironment surrounding many epithelial cancers. Here, we show that GDNF stimulation of RET(+)/GFR alpha 1(+) MCF7 breast cancer cells in vitro enhanced cell proliferation and survival, and promoted cell scattering. Moreover, in tumor xenografts, GDNF expression was found to be up-regulated on the infiltrating endogenous fibroblasts and to a lesser extent by the tumor cells themselves. Finally, the inflammatory cytokines tumor necrosis factor-alpha and interleukin-1 beta, which are involved in tumor promotion and development, were found to act synergistically to up-regulate GDNF expression in both fibroblasts and tumor cells. These data indicate that GDNF can act as an important component of the inflammatory response in breast cancers and that its effects are mediated by both paracrine and autocrine stimulation of tumor cells via signaling through the RET and GFR alpha 1 receptors.
Similar articles
-
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6. Cancer Res. 2013. PMID: 23650283 Free PMC article.
-
Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR alpha-1, and GFR alpha-2.Cancer Res. 1998 May 15;58(10):2158-65. Cancer Res. 1998. PMID: 9605760
-
Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase.Mol Cell Neurosci. 1998 May;11(1-2):47-63. doi: 10.1006/mcne.1998.0667. Mol Cell Neurosci. 1998. PMID: 9608533
-
Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF).Microsc Res Tech. 1999 May 15-Jun 1;45(4-5):292-302. doi: 10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.0.CO;2-8. Microsc Res Tech. 1999. PMID: 10383122 Review.
-
Intracellular RET signaling pathways activated by GDNF.Cell Tissue Res. 2020 Oct;382(1):113-123. doi: 10.1007/s00441-020-03262-1. Epub 2020 Aug 20. Cell Tissue Res. 2020. PMID: 32816064 Review.
Cited by
-
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.Biochem Pharmacol. 2023 Oct;216:115751. doi: 10.1016/j.bcp.2023.115751. Epub 2023 Aug 16. Biochem Pharmacol. 2023. PMID: 37595672 Review.
-
Non-coding RNA's prevalence as biomarkers for prognostic, diagnostic, and clinical utility in breast cancer.Funct Integr Genomics. 2023 Jun 4;23(2):195. doi: 10.1007/s10142-023-01123-y. Funct Integr Genomics. 2023. PMID: 37270446 Review.
-
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Cancer Res. 2023 Oct 2;83(19):3237-3251. doi: 10.1158/0008-5472.CAN-22-3484. Cancer Res. 2023. PMID: 37071495 Free PMC article.
-
RET signaling in breast cancer therapeutic resistance and metastasis.Breast Cancer Res. 2023 Mar 14;25(1):26. doi: 10.1186/s13058-023-01622-7. Breast Cancer Res. 2023. PMID: 36918928 Free PMC article. Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
